Background-Decreased synthesis of the predominant secretory human colonic mucin (MUC2) occurs during active ulcerative colitis. Aims-To study possible alterations in mucin sulphation and mucin secretion, which could be the cause of decreased mucosal protection in ulcerative colitis. (Gut 1999;44:387-393) 
Ulcerative colitis is a chronic inflammatory bowel disease of unknown origin, and is confined to the large bowel. 1 2 The mucosa of the colon is covered by mucus, which forms a protective layer against mechanical stress, luminal pathogens, and noxes. 3 As mucins form the structural components of mucus, 3 4 changes in the quantity or composition of secreted mucins in the colon could lead to diminished protection of the colonic mucosa, and thus play a role in the pathogenesis of ulcerative colitis. Indeed, in active ulcerative colitis, a number of specific changes have been reported: the mucus gel layer is thinner than normal, and goblet cells, which synthesise the secretory mucins, contain less mucin and also seem to be reduced in number. [5] [6] [7] In remission, the number and appearance of goblet cells returns to normal. 8 Furthermore, alterations in O-glycosylation of mucins have been reported in ulcerative colitis, such as in sialic acids and in sulphation. [9] [10] [11] Importantly, alterations in glycosylation of mucins, or in sulphation, may lead to a decreased protective capability of the colonic mucus barrier. 12 13 In man, mucins are encoded by a family of at least nine genes, of which the members are designated MUC1-8, including MUC5B and MUC5AC. 4 We have previously identified MUC2 as the predominant secretory mucin in the normal colon and also in the colon affected by ulcerative colitis. 14 15 In the efforts to understand the possible roles of colonic mucus in the pathogenesis of ulcerative colitis it is essential to concentrate on the MUC2 gene product. We have recently developed methods to quantify MUC2 biosynthesis in biopsy specimens obtained by endoscopy by performing metabolic labelling with radiolabelled amino acids. [16] [17] [18] [19] We showed that in active ulcerative colitis, MUC2 synthesis was significantly lowered to less than 40%, compared with both ulcerative colitis in remission and controls, whereas the MUC2 mRNA level remained constant, independently of the disease state. 16 However, it could not be determined whether secretion of MUC2 is altered in ulcerative colitis.
The aim of this study was to analyse whether sulphation and secretion of MUC2 are altered in ulcerative colitis, as such alterations may lead to diminished protection of the colonic mucosa. Therefore, we quantified the secretion and the sulphate incorporation of MUC2 in patients with active ulcerative colitis, ulcerative colitis in remission, and control patients. This was performed by metabolic labelling of colonic biopsy specimens, using [ The results show that in active ulcerative colitis, less MUC2 is secreted as MUC2 synthesis is decreased in active ulcerative colitis, while the secreted percentage of MUC2 remains unaltered. This is indicative for a specifically diminished mucosal protection in the ulcerative colitis colon. Additionally, in active ulcerative colitis, MUC2 is also undersulphated, while sulphated MUC2 is selectively secreted. As a result the sulphate content of secreted MUC2 is unaltered in active ulcerative colitis by a specific compensatory mechanism. As the data for both ulcerative colitis in remission and controls diVer significantly from the data for active ulcerative colitis, these aberrations are specific for the phase of active inflammation.
Materials and methods
Unless otherwise stated, chemicals were obtained from the following manufacturers: Gibco BRL, Gaithersburg, Maryland; Sigma, St Louis, Missouri; BioRad, Richmond, California; Amersham, Bucks, UK; and Kodak, Rochester, New York, USA.
HUMAN TISSUES
The following three patient groups were defined according to the accepted criteria of Truelove and Richards, 20 using clinical, endoscopic, and histological criteria: (1) control patients (n=12, seven men; mean age 47 years, range 20-75) who had a negative history for inflammatory bowel disease and had a normal colon. These patients were diagnosed with irri- S]-sulphate (Amersham). All biopsy specimens were then washed in medium to remove excess label and each specimen was chase incubated separately for four hours in 100 µl medium devoid of radiolabel, but containing non-radiolabelled cysteine/methionine and sulphate. All incubations took place in Eagle's minimum essential medium (E-MEM, Gibco BRL) supplemented with EMEM non-essential amino acids (Sigma), penicillin/streptomycin (Sigma), and glutamine (Sigma) at 37°C under 95% O 2 /5% CO 2 . All biopsy specimens or media were homogenised separately at 0°C in, respectively, 500 µl or 100 µl homogenisation buffer containing Triton X-100 (BDH, Poole, UK) and various protease inhibitors. The homogenates were stored at −70°C until further analysis as described in the following sections.
MEASUREMENT OF PROTEIN SYNTHESIS
Protein content was measured in the homogenate of each biopsy specimen, using a BCA protein assay kit and bovine serum albumin as a standard (Pierce, Rockford, Illinois, USA). Total incorporation of radioactivity in proteins was determined by liquid scintillation counting after trichloroacetic acid precipitation, as previously described. 16 
QUANTITATION OF RADIOLABELLED MUC2
This quantitation protocol has been described by Dekker et al. [17] [18] [19] By performing metabolic labelling of colonic biopsy specimens we have previously shown the biosynthesis and intracellular processing of MUC2. 14 15 21 We showed that after pulse labelling with [ ]-methionine/cysteine labelled mature MUC2, equal aliquots of each radiolabelled homogenate were analysed by reducing sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) with a 3% stacking and 4% running gel. Prestained molecular mass markers in the range 49.5 to 205 kDa (BioRad) were used. For reference to very high molecular mass molecules, metabolically labelled, unreduced rat gastric mucin precursors were used (molecular mass of monomer and dimer, 300 and 600 kDa, respectively). 22 Gels were fixed in 10% methanol/10% acetic acid, stained with periodic acid/SchiV's reagent (PAS, Sigma), dried and then used for quantitation of the MUC2 band by autoradiography using a PhosphorImager with ImageQuant software (Molecular Dynamics, B&L systems, Zoetermeer, The Netherlands). The elicited signal was expressed in arbitrary units. In addition, gels were exposed to x ray film (Biomax MR, Kodak).
The secreted percentage of MUC2 was calculated as the amount of MUC2 in the medium divided by the sum of the amount of MUC2 in the tissue and in the medium. This was multiplied by 100 to give the secreted percentage of MUC2. This quantitation protocol has been described by Dekker et al. 17 In order to analyse the total MUC2 (both radiolabelled and nonradiolabelled MUC2), dot blotting was performed. A 10 µl aliquot of 35 S-labelled homogenate was dot blotted onto nitrocellulose (Nitran, Schleier & Schuell, Dassel, Germany). 16 Briefly, the blot was incubated with a specific anti-MUC2 monoclonal antibody (WE9) which recognises the non-O-glycosylated unique termini of MUC2. 17 23 After washing, the blot was incubated for two hours with 125 I-labelled protein A (Amersham, specific activity 17.0 mCi/µg). Binding of 125 Ilabelled protein A to the monoclonal antibody WE9 was detected by autoradiography using a PhosphorImager (expressed in arbitrary units), after the blot was covered by two sheets of 3MM Whatman filter paper in order to eliminate background radiation of 35 S-label. For each biopsy specimen, the secreted percentage of MUC2 was calculated as the amount of MUC2 in the medium divided by the sum of the amount of MUC2 in the tissue and in the medium. This was multiplied by 100 to give the secreted percentage of MUC2.
STATISTICAL ANALYSIS
Analysis of variance was performed, followed by an unpaired t test. DiVerences were considered significant at p<0.05. Data were represented as mean (SEM).
Results

CHARACTERISTICS OF THE BIOPSY SPECIMENS
To correct for possible diVerences in size and in labelling eYciencies between the biopsy specimens, the protein content and incorporation of radiolabel of the specimens were determined. A measure of these parameters is the total protein synthesis, referred to as the viability, which is expressed as incorporated 35 S-label (cpm) per µg of tissue protein. Average viabilities of the biopsy specimens of each patient were calculated, followed by calculation of the mean viabilities (SEM) for each of the three patient groups. Between controls (mean 5145 (1452) cpm/µg), active ulcerative colitis (mean 4391 (833) cpm/µg), and ulcerative colitis in remission (mean 3415 (769) cpm/µg) no significant differences in viability were found. Between the duplicate biopsy specimens per patient, the viability diVered by only about 15% in each patient group.
IDENTIFICATION OF MATURE MUC2 IN COLONIC HOMOGENATES
By performing immunoprecipitations after pulse labelling of colonic biopsy specimens with [ 35 S]-methionine/cysteine followed by a four hour chase incubation, we previously showed that almost all radiolabelled MUC2 precursor had become mature O-glycosylated MUC2, which is detectable at about 550 kDa on SDS-PAGE. 14 15 21 23 Furthermore, we showed that this 550 kDa band was PAS stainable and, after western blotting, was recognised by anti-MUC2 antibodies. In fact, the expected molecular mass of mature MUC2 would be more than 2000 kDa. However, we showed that this mature mucin has an aberrantly high mobility on SDS-PAGE. 14 24 In the present study, mature MUC2 could also be identified by PAS staining on SDS-PAGE (fig 1) . After pulse labelling with [ (fig 2A,B) .
QUANTITATION OF SECRETION OF TOTAL MUC2
To quantify the secreted percentage of total MUC2, the homogenates of all 35 S-labelled biopsy specimens and their corresponding media were dot blotted and thereafter incubated with an anti-MUC2 monoclonal antibody and 125 I-labelled protein A, followed by quantitation. The secreted percentage of MUC2 was calculated and the values corresponding to the quadruplicate specimens of each patient were averaged and the mean total MUC2 secretion was calculated per patient group (fig 3) . For the three patients groups the mean total MUC2 secretion was in the range 28-30%. Between controls, active ulcerative colitis, and ulcerative colitis in remission no significant differences in the secreted percentage of total MUC2 were found (fig 3) . QUANTITATION In the diVerent patient groups, no correlation was found between any of the determined parameters (viability, secretion, [ 
S]-amino acids or [ 35 S]-sulphate and four hour chase incubations, the homogenates of the tissue (t) and the media (m) were analysed on reducing 4% SDS-PAGE and stained with PAS. The right hand arrow indicates the position of mature MUC2. The left hand arrow denotes the border between the running and stacking gel. Molecular mass markers of 600, 300, and 205 kDa are indicated on the left.
Figure 2 Identification of mature MUC2 in colonic homogenates. Representative examples of analyses of the biopsy specimens of each patient group are shown: controls (specimens 1 and 2), active ulcerative colitis (UC) (specimens 3 and 4), or ulcerative colitis in remission (specimens 5 and 6). Specimens were pulse labelled with either (A) [ 35 S]-amino acids (two duplicate specimens per patient) or (B) [ 35 S]-sulphate (two duplicate specimens per patient) and chase incubated for four hours, followed by analysis of the homogenates of the tissue (lanes t) and of the media (lanes m) on 4% reducing SDS-PAGE. The radioactive signal of the mature MUC2 band, indicated by the right hand arrows, was quantified using a PhosphorImager, followed by exposure to x ray film (shown here). The left hand arrows denote the border between the running and stacking gel. Molecular mass markers of
Discussion
As MUC2 is the prominent mucin in healthy colon and in colon aVected by ulcerative colitis, 14 15 and because mucins play an important role in cytoprotection, 25 we aimed to investigate possible alterations in biosynthesis or secretion of MUC2 in ulcerative colitis. Previously, we showed that the synthesis of MUC2 was decreased in active ulcerative colitis, compared with ulcerative colitis in remission and controls. 16 Following a similar quantitation protocol, we now set out to investigate whether the secretion or sulphation of MUC2 is altered in ulcerative colitis. Three comparable patient groups were studied: active ulcerative colitis, ulcerative colitis in remission, and a control group. In all patients, biopsy specimens were obtained from the same anatomically defined region of the colon. Firstly, we determined the viabilities of the specimens, and showed that these did not diVer significantly between the patient groups. This is similar to our previous results, 16 which showed that total protein synthesis of biopsy specimens did not change during short term in vitro culture, or between patients with active ulcerative colitis, ulcerative colitis in remission, or controls.
Metabolic 16 We have now shown that the secreted percentage of MUC2 is unaltered during active ulcerative colitis, and it therefore follows that the quantity of luminal MUC2 (the secreted MUC2) will be about threefold less during active ulcerative colitis. Therefore, the colonic mucus gel layer will contain less MUC2, and is thus thinner, weaker, and less protective in active ulcerative colitis. Interestingly, our findings explain the results of Pullan et al, who showed that the thickness of the colonic mucus gel is decreased in active ulcerative colitis. Importantly, sulphate is thought to confer resistance to enzymatic degradation of the mucus barrier 13 and therefore a decreased sulphate content of the mucus gel layer would be disadvantageous. On the other hand, an increased sulphate content of the mucus would also be disadvantageous, because more sulphate residues would be available to sulphate reducing bacteria. These bacteria are overrepresented in the bacterial flora of the colon during ulcerative colitis and produce sulphides that are highly toxic to the colonic mucosa. [26] [27] [28] The mechanisms that are responsible for the alterations in secretion of [ In conclusion, the colonic mucus barrier will be thinner and therefore less protective during active ulcerative colitis, because the absolute amount of MUC2 that is secreted is diminished. In addition, sulphated MUC2 is preferentially secreted during active ulcerative colitis. However, due to a decreased incorporation of sulphate into MUC2, the sulphate content of the secreted MUC2 (the number of sulphate residues per MUC2 molecule) will probably be normal in patients with active ulcerative colitis.
